Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Juni 2015 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Preliminary Approval of Securities Class Action Settlement

PHILADELPHIA, June 4, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that the United States District Court for the Eastern District of Pennsylvania has granted preliminary...
26. Mai 2015 12:46 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)

PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...
20. Mai 2015 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx to Present at the Marcum Microcap Conference in New York

PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) will present at the Marcum Microcap Conference being held at the Grand Hyatt Hotel in New York City on Wednesday, May...
13. Mai 2015 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2015

PHILADELPHIA, May 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2015. The net loss (including non-cash effects)...
11. Mai 2015 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...
28. April 2015 08:30 ET | Quelle: AIM ImmunoTech Inc.

Midtown Partners & Co, LLC Initiates Coverage and Arrowhead b.i.d. Issues Coverage Update on Hemispherx Biopharma

PHILADELPHIA, April 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") reported today that Midtown Partners &Co, LLC initiates coverage of...
24. März 2015 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, March 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European subsidiary, "Hemispherx Biopharma Europe...
23. März 2015 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus

PHILADELPHIA, March 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") will present integrated findings of new studies of Ampligen®...
20. März 2015 09:28 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2014

PHILADELPHIA, March 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the year ended December 31, 2014. The net loss (including non-cash effects) was...
09. März 2015 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand

PHILADELPHIA, March 9, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....

Vorherige Seite